"10.1371_journal.pone.0092717","plos one","2014-03-20T00:00:00Z","Samir K Gupta; Albert M Anderson; Ramin Ebrahimi; Todd Fralich; Hiba Graham; Valeska Scharen-Guivel; John F Flaherty; Claude Fortin; Robert C Kalayjian; Anita Rachlis; Christina M Wyatt","Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, United States of America; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America; Gilead Sciences, Inc., Foster City, California, United States of America; HÃ´pital Notre Dame of Montreal University Medical Center, Montreal, Canada; Division of Infectious Diseases, Metrohealth Medical Center, Cleveland, Ohio, United States of America; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America","Conceived and designed the experiments: SKG RE JFF. Performed the experiments: SKG AMA CF RCK AR CMW. Analyzed the data: SKG RE TF HG VS-G JFF. Wrote the paper: SKG AMA RE TF HG VS-G JFF CF RCK AR CMW.","SKG reports receiving unrestricted research grants from Gilead Sciences, Inc., Merck & Co., Inc., and Janssen Pharmaceuticals, travel support to present the current data at the 6th IAS Conference from Gilead Sciences, Inc., and consultancy fees from Bristol-Myers Squibb and Merck & Co., Inc. AMA reports receiving research support from Gilead Sciences, Inc. CF reports receiving research grants from Gilead Sciences Inc, speaker's fees, and travel support in 2010 from Gilead Sciences, Inc. AR reports receiving research grants from Gilead Sciences, Inc., Janssen Pharmaceuticals, AbbVie, and ViiV Healthcare and honoraria from Gilead Sciences, Inc., ViiV Healthcare, Janssen Pharmaceuticals, Merck & Co., Inc., AbbVie, and Bristol-Myers Squibb. CMW reports receiving unrestricted research grants from Gilead Sciences, Inc., and honoraria from Bristol-Myers Squibb. RE, TF, HB, VS-G, JF are employees of Gilead Sciences, Inc. and are stockholders in Gilead Sciences, Inc. RCK reports no conflicts. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2014","03","Samir K Gupta","SKG",11,TRUE,3,6,6,11,TRUE,TRUE,FALSE,0,NA,FALSE
